Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.30 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.30 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.30 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.30 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.30 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.30 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092228 | 1.00 | PDE4A (0.33) | PDE4APDE4BPDE4CPDE4DADRB3 | |
| SCHEMBL1093033 | 0.92 | PSD (0.34) | PSD | |
| SCHEMBL1092157 | 0.91 | PDE4D (0.32) | PDE4APDE4BPDE4CPDE4DRXRA | |
| SCHEMBL4191602 | 0.85 | XDH (0.35) | ADRB3ADRB1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL1092147 | 0.83 | PSD (0.35) | PSD | |
| SCHEMBL208541 | 0.80 | SRD5A2 (0.32) | PDE4APDE4BPDE4CPDE4DADRB3 | |
| SCHEMBL4060990 | 0.80 | SRD5A2 (0.32) | PDE4APDE4BPDE4CPDE4DADRB3 | |
| SCHEMBL1092618 | 0.79 | CHRM1 (0.33) | — | |
| SCHEMBL209090 | 0.77 | XDH (0.33) | ADRB3ADRB1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL4197218 | 0.76 | CHEK2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153807-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2021336-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090111809-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BUSH JULIE KAY | 2009-04-30 | — | — | US | disclosed |
| EP-2021336-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007127688-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111809-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD11B2 | PDE4A 713/4885PDE4B 882/4885PDE4C 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.